Author/Authors :
Davoudi, Ehsan Taghizadeh university of malaya - Faculty of Medicine - Department of Pharmacy, Malaysia , Noordin, Mohamed Ibrahim bin university of malaya - Faculty of Medicine - Department of Pharmacy, Malaysia , Javar, Hamid Akbari university of malaya - Faculty of Medicine - Department of Pharmacy, Malaysia , Javar, Hamid Akbari tehran university of medical sciences tums - Faculty of Pharmacy - Department of Pharmaceutics, تهران, ايران , Kadivar, Ali university of malaya - Faculty of Medicine - Department of Pharmacy, Malaysia , Sabeti, Bahare university of malaya - Faculty of Medicine - Department of Pharmacy, Malaysia
Abstract :
Cancer is among most important causes of death in recent decades. Whoever the renal cell carcinoma incidence is low but it seems it is more complicated than the other cancers in terms of pathophysiology and treatments. The purpose of this work is to provide an overview and also deeper insight to renal cell carcinoma and the steps which have been taken to reach more specific treatment and target therapy, in this type of cancer by developing most effective agents such as Sorafenib. To achieve this goal hundreds of research paper and published work has been overviewed and due to limitation of space in a paper just focus in most important points on renal cell carcinoma, treatment of RCC and clinical development of Sorafenib. The information presented this paper shows the advanced of human knowledge to provide more efficient drug in treatment of some complicated cancer such as RCC in promising much better future to fight killing disease.
Keywords :
Sorafenib , renal cancer , tyrosine kinase , VEGFR , Nexavar
